Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL
Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This is a phase II double blind, placebo-controlled, randomized study of Artesunate
suppositories for the treatment of HIV-negative men and women who have anal high grade
squamous intraepithelial lesions (anal HSIL)
Phase:
Phase 2
Details
Lead Sponsor:
Frantz Viral Therapeutics, LLC
Collaborators:
Amarex CRO Anal Dysplasia Clinic MidWest Laser Surgery Care University of California, San Francisco